Understanding vaccine responses in rhesus macaques
Core C: Systems Biology Core
This study is looking at how a specific vaccine works in monkeys to help improve vaccines for people, focusing on how a substance called IL-15 can boost the vaccine's effectiveness against a virus similar to HIV.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10897314 on NIH RePORTER |
What this research studies
This research focuses on generating detailed gene expression data to analyze how vaccines respond in rhesus macaques, particularly in relation to the RHCMV/SIV vaccine and the role of IL-15 in enhancing vaccine protection. The Systems Biology Core will utilize advanced techniques such as next-generation sequencing and NanoString nCounter analyses to assess immune responses from various biological samples. By managing and analyzing large datasets, the research aims to provide insights that could inform future vaccine development and improve protective strategies against SIV.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research are individuals involved in pre-clinical studies of SIV vaccines, particularly those with a focus on immune response analysis.
Not a fit: Patients not involved in SIV vaccine research or those without a relevant immune response condition may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccine strategies that enhance immune responses against SIV, potentially benefiting future vaccine development for humans.
How similar studies have performed: Other research has shown success in using high-throughput sequencing and functional genomics to analyze immune responses, indicating that this approach is promising and has been validated in similar contexts.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Gale, Michael — University of Washington
- Study coordinator: Gale, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.